Share these talks and lectures with your colleagues
Invite colleaguesWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- A chemical structure of Levetiracetam
- Originally discovered in sound-sensitive mice
- Antiepileptic drug discovery
- Inactivity in MES and s.c. PTZ seizure tests
- Levetiracetam in electroshock and PTZ seizures
- Protection against seizures in rat model
- Levetiracetam activity in GAERS model
- High therapeutic index of Levetiracetam
- No negative impact on cognitive function (1)
- No negative impact on cognitive function (2)
- Hyper-synchronization/excitability inhibition in vitro
- Levetiracetam inhibits hyper-synchronization
- Effect on development of amygdala kindling
- Effect on seizures in genetic models of epilepsy
- Chemical structure and pharmacological profile
- Mechanisms targeted in AED discovery (1)
- Inactivation of sodium channels
- Reduction of current through T-type Ca channels
- No conventional GABAergic effects
- Mechanisms targeted in AED discovery (2)
- Levetiracetam mechanism of action (1)
- Levetiracetam mechanism of action (2)
- Levetiracetam binding site - novel radioligand
- Levetiracetam binding site - characteristics
- SV2 proteins: candidates for the LEV binding site
- SV2 proteins knockout studies
- SV2A cloning and binding studies
- Affinities for hSV2A and anti-seizure potencies
- SV2A - novel intracellular and presynaptic target
- SV2A - broad-spectrum anticonvulsant target
- Kindling acquisition in SV2A (+/-) mice
- Levetiracetam studies in SV2A (+/-) mice (1)
- Levetiracetam studies in SV2A (+/-) mice (2)
- Target validation of SV2A
- Profile of new class of antiepileptic drugs
Topics Covered
- Levetiracetam
- Antiepileptic Drug Discovery
- Levetiracetam in electroshock and PTZ seizures
- Protection against seizures in rat model
- Levetiracetam activity in GAERS model
- Impact on cognitive function
- Hyper-synchronization / excitability inhibition in vitro
- Effect on development of amygdala kindling
- Effect on seizures in genetic models of epilepsy
- Inactivation of sodium channels
- Reduction of current through T-type Ca channels
- Levetiracetam mechanism of action
- SV2 proteins: candidates for the LEV binding site
- SV2A cloning and binding studies
- Levetiracetam studies in SV2A (+/-) mice
- Profile of new class of antiepileptic drugs
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Klitgaard, H. (2013, March 28). Discovery of Levetiracetam (Keppra(R)): The first SV2A ligand for the treatment of epilepsy [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 18, 2021, from https://hstalks.com/bs/2524/.Publication History
Financial Disclosures
- Dr. Henrik Klitgaard has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Other Talks in the Series: Small Molecule Drug Discovery
Other Talks in the Series: Drug Discovery and Development in the Neurosciences
Hide